Liming Chen1, Xiaojie Li1, Xiaojun Chen1. 1. Department of Oncology, The First Affiliated Hospital of Shantou University Medical College Shantou, Guangdong, China.
Abstract
BACKGROUND: MiRNAs might function as oncogenes or tumor suppressor genes in the tumorigenesis process. Dysregulation of miR-345 is a frequent event in many types of human cancers. However, the tissue miR-345 expression level in non-small cell lung cancer (NSCLC) and its potential clinical significance remains unknown. MATERIALS AND METHODS: Real-time PCR was conducted to evaluate the expression level of miR-345 in NSCLC tissues as well as cell lines. Then the association between tissue miR-345 expression level and clinical outcome was investigated. RESULTS: The expression level of miR-345 was significantly decreased in NSCLC tissues and cell lines compared with the controls (P<0.05; P<0.01). Tissue miR-345 expression level was associated with various clinicopathological parameters including LN metastasis (P=0.012), distant metastasis (P=0.007), TNM stage (P=0.008) and grade (P=0.030). In addition, the NSCLC patients in thelow tissue miR-345 expression group had significantly shorter 5-year overall survival time than those in the high tissue miR-345expression group (P=0.016). Multivariate analysis showed that tissue miR-345 was an independent risk factor for NSCLC (HR=3.921, 95% CI: 2.285-10.540; P=0.008). CONCLUSIONS: The expression level of miR-345 was reduced in NSCLC tissues and cell lines. Low tissue miR-345 expression was associated with progression and poor prognosis of NSCLC, indicating that tissue miR-345 may serve as a novel prognostic marker in NSCLC.
BACKGROUND: MiRNAs might function as oncogenes or tumor suppressor genes in the tumorigenesis process. Dysregulation of miR-345 is a frequent event in many types of humancancers. However, the tissue miR-345 expression level in non-small cell lung cancer (NSCLC) and its potential clinical significance remains unknown. MATERIALS AND METHODS: Real-time PCR was conducted to evaluate the expression level of miR-345 in NSCLC tissues as well as cell lines. Then the association between tissue miR-345 expression level and clinical outcome was investigated. RESULTS: The expression level of miR-345 was significantly decreased in NSCLC tissues and cell lines compared with the controls (P<0.05; P<0.01). Tissue miR-345 expression level was associated with various clinicopathological parameters including LN metastasis (P=0.012), distant metastasis (P=0.007), TNM stage (P=0.008) and grade (P=0.030). In addition, the NSCLCpatients in thelow tissue miR-345 expression group had significantly shorter 5-year overall survival time than those in the high tissue miR-345expression group (P=0.016). Multivariate analysis showed that tissue miR-345 was an independent risk factor for NSCLC (HR=3.921, 95% CI: 2.285-10.540; P=0.008). CONCLUSIONS: The expression level of miR-345 was reduced in NSCLC tissues and cell lines. Low tissue miR-345 expression was associated with progression and poor prognosis of NSCLC, indicating that tissue miR-345 may serve as a novel prognostic marker in NSCLC.
Authors: João A R Brito; Carolina C Gomes; André L S Guimarães; Kelma Campos; Ricardo S Gomez Journal: J Oral Pathol Med Date: 2013-09-11 Impact factor: 4.253
Authors: Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris Journal: Cancer Cell Date: 2006-03 Impact factor: 31.743
Authors: Mohamed Guled; Leo Lahti; Pamela M Lindholm; Kaisa Salmenkivi; Izhar Bagwan; Andrew G Nicholson; Sakari Knuutila Journal: Genes Chromosomes Cancer Date: 2009-07 Impact factor: 5.006
Authors: Wen Xue; James E Dahlman; Tuomas Tammela; Omar F Khan; Sabina Sood; Apeksha Dave; Wenxin Cai; Leilani M Chirino; Gillian R Yang; Roderick Bronson; Denise G Crowley; Gaurav Sahay; Avi Schroeder; Robert Langer; Daniel G Anderson; Tyler Jacks Journal: Proc Natl Acad Sci U S A Date: 2014-08-11 Impact factor: 11.205
Authors: K Mavridis; F Gueugnon; A Petit-Courty; Y Courty; A Barascu; S Guyetant; A Scorilas Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640
Authors: Sanjeev K Srivastava; Arun Bhardwaj; Sumit Arora; Nikhil Tyagi; Seema Singh; Joel Andrews; Steve McClellan; Bin Wang; Ajay P Singh Journal: Br J Cancer Date: 2015-08-06 Impact factor: 7.640
Authors: Rafal Bartoszewski; Michal Dabrowski; Bogdan Jakiela; Sadis Matalon; Kevin S Harrod; Marek Sanak; James F Collawn Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-08-05 Impact factor: 5.464
Authors: Ming Li; Wulin Shan; Bo Hong; Jinglu Zou; Hong Li; Dandan Han; Yang Zhang; Lailing Li; Dan Li; Wenchu Lin Journal: Sci Rep Date: 2020-07-29 Impact factor: 4.379